13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • DREAM3R

    Acronym: 

    DREAM3R

    ACTRN/NCT /ethics: 

    Scientific title: 

    DuRvalumab with chEmotherapy vs chemotherapy alone as first line treAtment in advanced, pleural Mesothelioma - a phase 3 Randomised trial

    Summary of trial and patient characteristics

    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Tumour Stream Mesothelioma
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Mesothelioma
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    DuRvalumab with chEmotherapy vs chemotherapy alone as first line treAtment in advanced, pleural Mesothelioma - a phase 3 Randomised trial

    Lay Summary

    DuRvalumab with chEmotherapy vs chemotherapy alone as first line treAtment in advanced, pleural Mesothelioma - a phase 3 Randomised trial

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    The Queen Elizabeth Hospital Pamela Cooper pamela.cooper@sa.gov.au 08 8222 6140 Dr Rachel Roberts-Thomson Not Yet Recruiting